Skip to main content
Erschienen in: Clinical Drug Investigation 7/2008

01.07.2008 | Original Research Article

Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally Impaired Subjects

Two Prospective, Multicentre, Open- Label, Parallel-Group Volunteer Studies

verfasst von: Samantha Abel, Richard Allan, Kuan Gandelman, Konrad Tomaszewski, David J. Webb, Dr Nolan D. Wood

Erschienen in: Clinical Drug Investigation | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives:

Since little is known regarding the pharmacokinetics of voriconazole in renally impaired patients, two prospective, open-label, parallel-group volunteer studies were conducted to estimate the effect of renal impairment on the pharmacokinetics of oral voriconazole and intravenous voriconazole solubilized with sulphobutylether-β-cyclodextrin (SBECD), respectively.

Methods:

In study A, male subjects with no (n = 6), mild (n = 6), moderate (n = 6) or severe (n = 6) renal impairment received one 200 mg dose of oral voriconazole. Voriconazole plasma levels were periodically assessed until 48 hours post-dose. In study B, male subjects with no (n = 6) or moderate (n = 7) renal impairment received multiple doses of intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily [day 1] then 3 mg/kg twice daily [days 2–6] followed by a final dose of 3 mg/kg on the morning of day 7) at an infusion rate of 3 mg/kg/h. Voriconazole plasma levels were periodically assessed until 36 hours following the final dose. Pharmacokinetics were determined by non-compartmental methods.

Results:

The pharmacokinetics of voriconazole were unaffected in subjects with any degree of renal impairment in both studies. In study B, clearance of SBECD was proportional to creatinine clearance (r2 = 0.857). Although two subjects had >30% increase in serum creatinine from baseline, these changes did not correlate with SBECD trough levels (r2 = 0.053). The majority of subjects with moderate renal insufficiency were able to tolerate 7 days of intravenous voriconazole solubilized with SBECD.

Conclusion:

These data suggest that renal impairment does not affect the pharmacokinetics of voriconazole. Furthermore, in subjects with moderate renal impairment, there is a strong linear correlation between SBECD clearance and creatinine clearance, and elevated SBECD levels do not necessarily correlate with increased serum creatinine levels (an indicator of worsening renal function).
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531–3PubMedCrossRef Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531–3PubMedCrossRef
2.
Zurück zum Zitat Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999; 43: 169–71PubMedCrossRef Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999; 43: 169–71PubMedCrossRef
3.
Zurück zum Zitat Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198–202PubMed Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198–202PubMed
4.
Zurück zum Zitat Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today (Barc) 2001; 37: 135–48 Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today (Barc) 2001; 37: 135–48
5.
Zurück zum Zitat Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40–79PubMed Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40–79PubMed
6.
Zurück zum Zitat Koltin Y, Hitchcock CA. Current and emerging azole antifungal agents. Curr Opin Chem Biol 1997; 1: 176–82PubMedCrossRef Koltin Y, Hitchcock CA. Current and emerging azole antifungal agents. Curr Opin Chem Biol 1997; 1: 176–82PubMedCrossRef
7.
Zurück zum Zitat Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man [abstract no. F78]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco (CA) Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man [abstract no. F78]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco (CA)
8.
Zurück zum Zitat Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546–53PubMedCrossRef Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546–53PubMedCrossRef
9.
Zurück zum Zitat Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole: a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56Suppl. 1: S2–9CrossRef Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole: a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56Suppl. 1: S2–9CrossRef
10.
Zurück zum Zitat Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56Suppl. 1: S10–6CrossRef Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56Suppl. 1: S10–6CrossRef
11.
Zurück zum Zitat Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395–402PubMedCrossRef Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395–402PubMedCrossRef
12.
Zurück zum Zitat Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649–63PubMedCrossRef Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649–63PubMedCrossRef
13.
Zurück zum Zitat Patterson BE, Roffey S, Jezequel SG, et al. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man [abstract no. F79]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco (CA) Patterson BE, Roffey S, Jezequel SG, et al. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man [abstract no. F79]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco (CA)
14.
Zurück zum Zitat Ikeda Y, Umemura K, Kondo K, et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 586–8CrossRef Ikeda Y, Umemura K, Kondo K, et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 586–8CrossRef
15.
Zurück zum Zitat Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913–58PubMedCrossRef Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913–58PubMedCrossRef
17.
Zurück zum Zitat Tomaszewski K, Purkins L. The pharmacokinetics and safety of sulphobutylether-β-cyclodextrin (SBECD) [abstract no. A-23]. 41st Interscience Conference Antimicrobial Agents Chemotherapy; 2001 Dec 16–19; Chicago (IL) Tomaszewski K, Purkins L. The pharmacokinetics and safety of sulphobutylether-β-cyclodextrin (SBECD) [abstract no. A-23]. 41st Interscience Conference Antimicrobial Agents Chemotherapy; 2001 Dec 16–19; Chicago (IL)
18.
Zurück zum Zitat Guidance for Industry: pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 1998 May Guidance for Industry: pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 1998 May
19.
Zurück zum Zitat Pennick GJ, Clark M, Sutton DA, et al. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents and Chemother 2003; 47: 2348–50CrossRef Pennick GJ, Clark M, Sutton DA, et al. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents and Chemother 2003; 47: 2348–50CrossRef
20.
Zurück zum Zitat Gage R, Venn RF, Bayliss MAJ, et al. Fluorescence determination of sulphobutylether-β-cyclodextrin in human plasma by size exclusion chromatography with inclusion complex formation. J Pharm Biomed Anal 2000; 22: 773–80PubMedCrossRef Gage R, Venn RF, Bayliss MAJ, et al. Fluorescence determination of sulphobutylether-β-cyclodextrin in human plasma by size exclusion chromatography with inclusion complex formation. J Pharm Biomed Anal 2000; 22: 773–80PubMedCrossRef
21.
Zurück zum Zitat Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41CrossRef Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41CrossRef
22.
Zurück zum Zitat Zhou Q, Yamamoto I, Fukuda T, et al. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur J Clin Pharmacol 1999; 55: 43–7PubMedCrossRef Zhou Q, Yamamoto I, Fukuda T, et al. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur J Clin Pharmacol 1999; 55: 43–7PubMedCrossRef
23.
Zurück zum Zitat von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 6CrossRef von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 6CrossRef
24.
Zurück zum Zitat Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435–42PubMedCrossRef Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435–42PubMedCrossRef
25.
Zurück zum Zitat Kullberg BJ. Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment for candidaemia in non-neutropenic patients [abstract no. 10.1111/ j.H98-743X.2004.902_o245.x]. 14th European Society of Clinical Microbiology and Infectious Diseases; 2004 May 1–4; Prague Kullberg BJ. Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment for candidaemia in non-neutropenic patients [abstract no. 10.1111/ j.H98-743X.2004.902_o245.x]. 14th European Society of Clinical Microbiology and Infectious Diseases; 2004 May 1–4; Prague
26.
Zurück zum Zitat Alvarez-Lerma F, Nicolás-Arfelis JM, Rodriguez-Borregán JC, et al. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005; 17: 417–27PubMed Alvarez-Lerma F, Nicolás-Arfelis JM, Rodriguez-Borregán JC, et al. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005; 17: 417–27PubMed
Metadaten
Titel
Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally Impaired Subjects
Two Prospective, Multicentre, Open- Label, Parallel-Group Volunteer Studies
verfasst von
Samantha Abel
Richard Allan
Kuan Gandelman
Konrad Tomaszewski
David J. Webb
Dr Nolan D. Wood
Publikationsdatum
01.07.2008
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 7/2008
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200828070-00002

Weitere Artikel der Ausgabe 7/2008

Clinical Drug Investigation 7/2008 Zur Ausgabe

Correspondence

The Authors’ Reply